SOLUBILITY ENHANCEMENT OF LABETALOL HYDROCHLORIDE BY USING LIQUISOLID TECHNIQUE FOR MANAGEMENT OF HYPERTENSION

Background: Hypertension is the most common disorder affecting different age groups of people. The increased blood pressure creates discomfort in the patients; these cardiovascular diseases are risky which can lead to “mortality and morbidity”. Labetalol hydrochloride is an anti-hypertensive drug used to treat high blood pressure and Angina. These compounds possess less water solubility and low bioavailability (25%). Objective: The current study is aimed to develop Labetalol hydrochloride Liquisolid Tablets to enhance its solubility. Results: The in-vitro dissolution studies showed enhanced drug release at 98.43% with Avicel PH102 as carrier and 96.54% with Fujicalin as the carrier. Hence F3 with 98.43% drug release was considered the optimized formulation. The optimized formulation batch F3 was subjected to stability studies as per the ICH guidelines. There was no significant change observed. Conclusion: It can be concluded that labetalol hydrochloride was successfully incorporated as a liquisolid tablet by the direct compression method. The direct compression method employed was easy and can be widely used’. The powder blend of F3 containing avicel pH 102 as a carrier material showed excellent flow ability, liquid retention potential compared to the Fujicalin as a carrier. Hence F3 is considered optimized. The in-vitro drug release confirmed the enhanced drug release from the liquisolid tablets. The stability studies revealed the formulation was stable.